Peptide Comparison
SetmelanotidevsLiraglutide
Targeted MC4R agonist for rare genetic obesity caused by melanocortin pathway defects
FDA-approved once-daily GLP-1 receptor agonist (Victoza/Saxenda) that reduces HbA1c by 0.9–1.6%, promotes 5–10% body weight loss, and demonstrated a 13% reduction in major adverse cardiovascular events in the landmark LEADER trial of 9,340 patients
At a Glance
Quick
comparison
Dose Range
Setmelanotide
0.5 mg–3 mg mg
Liraglutide
0.6–3.0 mg
Frequency
Setmelanotide
Once daily
Liraglutide
Once daily
Administration
Setmelanotide
subcutaneous injection
Liraglutide
Subcutaneous injection
Cycle Length
Setmelanotide
Ongoing/indefinite
Liraglutide
Ongoing/indefinite
Onset Speed
Setmelanotide
Moderate (1-2 weeks)
Liraglutide
Gradual (3-4 weeks)
Evidence Level
Setmelanotide
Strong human trials (Phase 3 or FDA approved)
Liraglutide
Strong human trials (Phase 3 or FDA approved)
Efficacy
Benefit
ratings
Weight Management
Metabolic Health
Quality of Life
Metabolic
Healing & Recovery
Technical Data
Compound
specifications
Setmelanotide
Molecular Formula
C49H68N18O9S2
Molecular Weight
1,117.3 Da
Half-Life
~11 hours
Bioavailability
~79% subcutaneous bioavailability
CAS Number
920014-72-8
Liraglutide
Molecular Formula
C172H265N43O51
Molecular Weight
3,751 Da
Half-Life
~13 hours (enabling once-daily dosing); Tmax 8–12 hours; steady state in 3–5 days
Bioavailability
~55% after subcutaneous injection; >98% plasma protein binding to albumin via C16 fatty acid moiety
CAS Number
204656-20-2
Protocols
Dosing
tiers
Setmelanotide
Liraglutide
Applications
Best
suited for
Setmelanotide
Treating obesity caused by confirmed POMC deficiency mutations
Setmelanotide is particularly well-suited for individuals focused on treating obesity caused by confirmed pomc deficiency mutations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Managing obesity from PCSK1 or LEPR genetic defects
Setmelanotide is particularly well-suited for individuals focused on managing obesity from pcsk1 or lepr genetic defects. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing hyperphagia and body weight in Bardet-Biedl syndrome
Setmelanotide is particularly well-suited for individuals focused on reducing hyperphagia and body weight in bardet-biedl syndrome. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Addressing early-onset severe obesity with identified melanocortin pathway mutations
Setmelanotide is particularly well-suited for individuals focused on addressing early-onset severe obesity with identified melanocortin pathway mutations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Liraglutide
Type 2 diabetes patients with HbA1c >7% requiring both glycemic control and weight management
Liraglutide is particularly well-suited for individuals focused on type 2 diabetes patients with hba1c >7% requiring both glycemic control and weight management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Obese individuals (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities seeking FDA-approved pharmacotherapy
Liraglutide is particularly well-suited for individuals focused on obese individuals (bmi ≥30) or overweight (bmi ≥27) with weight-related comorbidities seeking fda-approved pharmacotherapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy
Liraglutide is particularly well-suited for individuals focused on patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile
Liraglutide is particularly well-suited for individuals focused on patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Side
effects
Setmelanotide
Common
- Skin Hyperpigmentation
- Injection Site Reactions
- Nausea
- Diarrhea
Uncommon
- Hair Color Darkening and Nevus Changes
Serious
- Depression and Suicidal Ideation
Liraglutide
Common
- Nausea
- Diarrhea
- Vomiting
- Decreased appetite and headache
Uncommon
- Injection site reactions
Serious
- Acute pancreatitis
- Gallbladder disease
Research Status
Safety
& evidence
Setmelanotide
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
FDA approved for this use
Safety Overview
Setmelanotide demonstrates favorable tolerability in Phase 3 trials with safety data from over 200 patients across POMC, PCSK1, LEPR-deficient, and Bardet-Biedl syndrome populations. The most common adverse effect is dose-dependent skin hyperpigmentation (>60% of patients) due to off-target MC1R activation on melanocytes—a manageable, reversible pharmacological effect rather than true toxicity. Serious psychiatric adverse events including depression and suicidal ideation require baseline mental health screening and ongoing monitoring in all patients.
Contraindications
- xKnown hypersensitivity to setmelanotide or any excipients
- xObesity not caused by POMC, PCSK1, LEPR deficiency or Bardet-Biedl syndrome
- xPatients without genetic confirmation of melanocortin pathway mutations
- xUse during pregnancy (animal studies suggest potential fetal harm)
Liraglutide
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
FDA approved for this use
Safety Overview
Liraglutide (Victoza, Saxenda) is FDA-approved with extensive safety data from 15+ years of clinical use in diabetes (GLP-1 agonist) and obesity indications. Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 30-40% of patients during dose escalation but diminish significantly after 2-3 weeks of stable dosing. Black box warnings include risk of medullary thyroid carcinoma and pancreatitis, though absolute incidence remains rare. Injection site reactions are minimal. The compound shows no hepatotoxicity, nephrotoxicity, or major drug interactions at approved doses.
Contraindications
- xPersonal or family history of medullary thyroid carcinoma (MTC) — black box warning based on rodent thyroid C-cell tumor findings
- xMultiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- xKnown hypersensitivity to liraglutide or any excipients
- xPregnancy (Saxenda indication) — contraindicated; effective contraception required
Decision Guide
Which is
right for you?
Choose Setmelanotide if...
- Treating obesity caused by confirmed POMC deficiency mutations
- Managing obesity from PCSK1 or LEPR genetic defects
- Reducing hyperphagia and body weight in Bardet-Biedl syndrome
- Addressing early-onset severe obesity with identified melanocortin pathway mutations
Choose Liraglutide if...
- Type 2 diabetes patients with HbA1c >7% requiring both glycemic control and weight management
- Obese individuals (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities seeking FDA-approved pharmacotherapy
- Patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy
- Patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile